This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Yuhong Du Articles by Chiosis, G. Search for Related Content PubMed PubMed Citation Articles by Yuhong Du, Articles by Chiosis, G. Pubmed/NCBI databases Medline Plus Health Information Cancer Social Bookmarking                         What's this?

High-Throughput Screening Fluorescence Polarization Assay for Tumor-Specific Hsp90

Department of Pharmacology, Emory University School of Medicine and Emory Chemical Biology Discovery Center, Atlanta, Georgia

Kamalika Moulick

Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Anna Rodina

Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Julia Aguirre

Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Sara Felts

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota

Raymond Dingledine

Department of Pharmacology, Emory University School of Medicine and Emory Chemical Biology Discovery Center, Atlanta, Georgia

Haian Fu

Department of Pharmacology, Emory University School of Medicine and Emory Chemical Biology Discovery Center, Atlanta, Georgia

Gabriela Chiosis

Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, chiosisg{at}mskcc.org

Heat shock protein 90 (Hsp90) is a molecular chaperone that has emerged as an important target in cancer and several other diseases, such as neurodegenerative diseases, nerve injuries, inflammation, and infection. Discovery of novel agents that inhibit Hsp90 and have druglike properties is therefore a major focus in several academic and industrial laboratories. In this study, the authors describe the development and optimization in a 384-well format of a novel assay for the identification of Hsp90 inhibitors using fluorescence polarization, which measures competitive binding of red-shifted fluorescently labeled geldanamycin (GM-cy3B) to Hsp90 found in the NCI-N417 small-cell lung carcinoma cells. The authors demonstrate that GMcy3B binds with high affinity and specificity to cellular Hsp90. The assay results in excellent signal-to-noise ratios (>10) and Z' values (>0.75) at tracer concentrations greater than 4 nM and 1 µg/well of total NCI-N417 protein, indicating a robust assay. It also equilibrates after 5 h of incubation at room temperature and remains stable for up to 24 h. Furthermore, it is a simple mix-and-read format that is cost-effective and uses only low amounts of fluorophore and cell lysates. A study using more than 15,000 compounds from the National Institutes of Health Molecular Libraries Screening Center Network was performed to validate its performance in a high-throughput screening format. (Journal of Biomolecular Screening 2007:915-924)

Key Words: tumor Hsp90 • fluorescence polarization • GM-cy3B • small-cell lung carcinoma • 384-well format

Journal of Biomolecular Screening, Vol. 12, No. 7, 915-924 (2007)
DOI: 10.1177/1087057107306067


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?